Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795442 | 1.00 | GLS (0.39) | GLSGLANPSR1 | |
| SCHEMBL2720279 | 1.00 | GLS (0.39) | GLSGLANPSR1 | |
| SCHEMBL797160 | 0.82 | GLS (0.38) | GLS | |
| SCHEMBL21726164 | 0.77 | GLS (0.38) | GLSGLANPSR1 | |
| SCHEMBL12372230 | 0.77 | GLS (0.38) | GLSGLANPSR1 | |
| SCHEMBL264858 | 0.77 | GLS (0.38) | GLSGLANPSR1 | |
| SCHEMBL797083 | 0.77 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL8775651 | 0.77 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL797085 | 0.77 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL797084 | 0.77 | GLS (0.33) | GLSGLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA AS (DK) | 2025-06-19 | — | — | US | disclosed |
| EP-4486737-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO Pharma A/S (DK) | 2025-01-08 | — | — | EP | disclosed |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-117279907-A | Pyrrolidone derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023166172-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166172-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-09-07 | — | — | WO | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-7846954-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846954-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-07 | — | — | US | disclosed |
| WO-2010002956-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-07 | — | — | US | disclosed |
| EP-0804430-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5656662-A | TREATING OR PREVENTING ATHEROSCLEROTIC DISORDERS, INHIBITING INFLAMMATORY CYTOKINES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5504107-A | ANTICOAGULANTS, PREVENTING ATHEROSCLEROSIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1995032194-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | GLS 1123/4885GLA 514/4885NPSR1 3652/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | GLS 135/4885GLA 1873/4885NPSR1 745/4885 |
| US-20100004300-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | GLS 263/4885GLA 4378/4885NPSR1 1306/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | GLS 563/4885GLA 2381/4885NPSR1 3281/4885 |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | GLS 1007/4885GLA 2949/4885NPSR1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.